Literature DB >> 2526672

Cellular changes during the infusion of high dose intravenous immunoglobulin.

A C Newland1, M G Macey, P A Veys.   

Abstract

With the ever widening group of autoimmune conditions that are beneficially affected by infusions of high dose immunoglobulin the possible mechanisms of action of such therapy appear increasingly complex. Fc mediated blockade of the mononuclear phagocyte system is an acknowledged early effect. This is, however, accompanied by a decrease of neutrophil counts which suggests that IgG binding to the neutrophil may be a mechanism of action. The decrease of neutrophil counts is transient but in immune thrombocytopenia is inversely proportional to the platelet response observed. In parallel to the effect on the neutrophil there are changes in the lymphocyte subsets with reversal of the T helper/suppressor ratio and alterations in the individual cellular constituents of each subset that correlate with the clinical response. The observed changes in B cell numbers and function suggest that T dependent and independent antibody production is effected by intravenous immunoglobulin. It is increasingly clear that in ITP at least the clinical response to IV IgG is a summation of several cellular events and their balance reflects the ultimate outcome. It may eventually be possible to use these observations to predict the likely outcome in the individual patient of this mode of therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2526672     DOI: 10.1007/bf00320254

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  23 in total

1.  Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody.

Authors:  S B Clarkson; J B Bussel; R P Kimberly; J E Valinsky; R L Nachman; J C Unkeless
Journal:  N Engl J Med       Date:  1986-05-08       Impact factor: 91.245

2.  SLE anticoagulant: transient inhibition by high dose immunoglobulin infusions.

Authors:  B A McVerry; R Spearing; A Smith
Journal:  Br J Haematol       Date:  1985-11       Impact factor: 6.998

3.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

4.  Neutropenia following intravenous immunoglobulin.

Authors:  P A Veys; M G Macey; C M Owens; A C Newland
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-25

5.  Characterization of human lymphocyte subpopulations: alloreactive cytotoxic T-lymphocyte precursor and effector cells are phenotypically distinct from Leu 2+ suppressor cells.

Authors:  L T Clement; M K Dagg; A Landay
Journal:  J Clin Immunol       Date:  1984-09       Impact factor: 8.317

Review 6.  Control idiotope expression by monoclonal anti-idiotope antibodies.

Authors:  G Kelsoe; M Reth; K Rajewsky
Journal:  Immunol Rev       Date:  1980       Impact factor: 12.988

7.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

Authors:  J Fehr; V Hofmann; U Kappeler
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

8.  High-dose intravenous IgG in adults with autoimmune thrombocytopenia.

Authors:  A C Newland; J G Treleaven; R M Minchinton; A H Waters
Journal:  Lancet       Date:  1983-01-15       Impact factor: 79.321

Review 9.  The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease.

Authors:  J B Bussel; M W Hilgartner
Journal:  Br J Haematol       Date:  1984-01       Impact factor: 6.998

10.  Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies.

Authors:  N E Adelman; D L Watling; H O McDevitt
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

View more
  1 in total

1.  Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin.

Authors:  C Richter; A Schnabel; E Csernok; K De Groot; E Reinhold-Keller; W L Gross
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.